Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX009 and IN10018 in Advanced Solid Tumours
NCT06708663Phase 2Recruiting
- Sponsor
- Hanx Biopharmaceuticals
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HX009, ifebemtinib in biliary tract cancer (BTC), melanoma, solid tumor, sponsored by Hanx Biopharmaceuticals. Started Jan 2025; status: recruiting.
02
Drugs
HX009ifebemtinib
03
Conditions
biliary tract cancer (BTC)melanomasolid tumor
Beyond the preview
Go deeper on NCT06708663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708663.